Morgan Stanley
BBOT

Morgan Stanley’s BridgeBio Oncology BBOT Stock Holding History

Morgan Stanley’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8K Sell
3,380
-39,994
-92% -$334K ﹤0.01% 6728
2026
Q1 		$388K Buy
43,374
+29,022
+202% +$312K ﹤0.01% 5599
2025
Q4 		$180K Buy
14,352
+13,491
+1,567% +$163K ﹤0.01% 5968
2025
Q3 		$9.97K Buy
+861
New +$8.97K ﹤0.01% 6905

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley's BBOT Position: Q2 2026 in Review

Morgan Stanley reduced its BridgeBio Oncology (BBOT) stake by 92% in Q2 2026, selling an estimated $334K and leaving 3,380 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6728.

Morgan Stanley first reported a position in BBOT in Q3 2025 and has held it in 4 quarters since. The position peaked at $388K in Q1 2026. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Morgan Stanley held 3,380 shares of BridgeBio Oncology worth $25.8K as of Q2 2026.
  • Morgan Stanley sold 39,994 BridgeBio Oncology shares in Q2 2026, an estimated $334K.
  • BridgeBio Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6728 holding.
  • Morgan Stanley first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 4 quarters since.
  • Morgan Stanley's BridgeBio Oncology position peaked at $388K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.